[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100466353":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":46,"responsibleParty":64,"collaborators":66,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":41,"eligibilityCriteria":74,"healthyVolunteers":71,"sex":75,"minAge":76,"maxAge":41,"enrollmentInfo":77,"targetDuration":41,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":89,"whyStopped":41,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intensive BP Arm","EXPERIMENTAL","Participants randomized into the Intensive treatment group will have a goal of SBP \\\u003C120 mmHg. A two- or three-drug regimen should be initiated at randomization for most participants. Drug doses should be increased and\u002For additional antihypertensive medications should be added at each visit in the intensive treatment group, usually at monthly intervals, until the participant's goal of \\\u003C120 mmHg has been reached or the local investigator decides no further antihypertensive medications may be added.",[13],"Drug: Intensive BP Arm",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard BP Arm","ACTIVE_COMPARATOR","Participants randomized into the Standard treatment group will have a goal of SBP \\\u003C140 mmHg. It is expected to achieve a SBP of 135-139 mmHg in as many participants as possible. Medication dose titration or addition of another drug is indicated if SBP is ≥160 mmHg at a single visit or is ≥140 mmHg at two consecutive visits. Down titration should be carried out if the SBP is \\\u003C130 mmHg at a single visit or \\\u003C135 mmHg at two consecutive visits.",[19],"Drug: Standard BP Arm",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Participants in the Intensive BP treatment group have a goal of SBP \\\u003C120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals: Angiotension converting enzyme (ACE)-inhibitors;Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics",[9],[26],"Control of SBP to \u003C120 mmHg",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Participants in the Standard BP treatment group have a goal of SBP \\\u003C140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.",[15],[31],"Control of SBP to \u003C140 mmHg",[33],{"name":34,"affiliation":35,"role":36},"Jing Li","Chinese Academy of Medical Sciences, Fuwai Hospital","PRINCIPAL_INVESTIGATOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":41,"email":42},"Jing Li, Ph.D","CONTACT",null,"jing.li@fwoxford.org",{"name":44,"role":40,"phone":41,"phoneExt":41,"email":45},"Xiaofang Yan, M.S.","xiaofang.yan@fwoxford.org",[47],{"facility":48,"status":41,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Fuwai Hospital, Chinese Academy of Medical Sciences","Beijing","Beijing Municipality","100037","China","CN",{"type":55,"coordinates":56},"Point",[57,58],116.39723,39.9075,{"lat":58,"lon":57},[61],{"name":62,"role":40,"phone":41,"phoneExt":41,"email":63},"Ying Sun, B.A.","ying.sun@fwoxford.org",{"type":65,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR",[67],{"name":35,"class":68},"OTHER","100466353","effects-of-intensive-systolic-blood-pressure-lowering-treatment-on-out-of-office-blood-pressure---an-ancillary-study-to-effects-of-intensive-systolic-blood-pressure-lowering-treatment-in-reducing-risk-of-vascular-events-esprit-study-100466353",false,"NCT05352633","Effects of Intensive Systolic Blood Pressure Lowering Treatment on Out-of-office Blood Pressure - an Ancillary Study to Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study","Inclusion Criteria:\n\n1. eligible for the follow up of the main study;\n2. content to participate in the sub-study.\n\nExclusion Criteria:\n\n1. frequently working during night-time;\n2. the non - dominant arm could not wear 24-hour ambulatory blood pressure monitoring due to radiation therapy or physical impairment;\n3. keep engaged in out-door activities of high physical intensity, e.g. farming or porter, etc.;\n4. life expectancy is less than 1 year; such as diagnosed with heart failure, cancer, or end-stage renal disease;\n5. the difference of clinical systolic pressure between upper arms was more than 10 mmHg;\n6. unable to use smart-phone to upload family blood pressure monitoring data.","ALL","50 Years",{"count":78,"type":79},710,"ESTIMATED","INTERVENTIONAL",[82],"NA","This study aims to evaluate the effect of intensive treatment (a target clinic based systolic blood pressure(BP) \\\u003C120mmHg) on 24-hour ambulatory blood pressure and home blood pressure, as well as the effect on White-coat uncontrolled hypertension and masked uncontrolled hypertension, compared with standard treatment (a target clinic based systolic BP \\\u003C140mmHg).",[85],"Blood Pressure",[87,88],"Intense Pressure Lowering Treatment","Out-of-office Blood Pressure","UNKNOWN","2022-06-25",{"date":92,"type":93},"2022-06-28","ACTUAL",{"date":95,"type":79},"2022-07-18",{"date":97,"type":79},"2023-09-30",{"name":5,"class":6},1]